ANK3: A Potential Drug Target and Biomarker (G288)

Target Name: ANK3

NCBI ID: G288

ANK3

ANK3: A Potential Drug Target and Biomarker

Ankyrin 3 (ANK3) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the stem-cell proliferation and differentiation, and its dysfunction has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

The ANK3 gene is located on chromosome 6 and encodes a protein known as ANK3, which is involved in the regulation of stem-cell proliferation and differentiation. The ANK3 protein has been shown to play a role in the development and maintenance of neural stem cells, which are crucial for the development and maintenance of the nervous system.

In addition to its role in stem-cell biology, ANK3 has also been shown to be involved in the regulation of cell cycle progression and the assembly of chromatin. It has been shown to interact with various cellular signaling pathways, including the TGF-β pathway, which plays a critical role in the regulation of cell growth, differentiation, and survival.

The ANK3 gene has also been implicated in the development and progression of various diseases, including cancer. For example, studies have shown that ANK3 is often overexpressed in various types of cancer, and that its dysfunction is associated with cancer stem cells. In addition, ANK3 has also been shown to be involved in the regulation of cancer cell migration and invasion, which are critical steps in the development of cancer.

As a potential drug target, ANK3 has been the focus of intense research in recent years. Studies have shown that ANK3 can be targeted by various small molecules, including inhibitors of the TGF-β pathway. In addition, ANK3 has also been shown to play a role in the regulation of the immune system, and that its dysfunction is associated with an increased risk of cancer and other diseases.

In addition to its potential as a drug target, ANK3 has also been shown to be a potential biomarker. Studies have shown that ANK3 levels are elevated in various types of cancer, and that they can be used as a diagnostic or predictive marker for cancer. In addition, ANK3 has also been shown to be involved in the regulation of cellular processes that are critical for the development and maintenance of tissues, including the regulation of inflammation and fibrosis.

Overall, ANK3 is a promising candidate for drug targeting and biomarker research. Its involvement in the regulation of stem-cell proliferation and differentiation, as well as its involvement in the regulation of cell cycle progression and the assembly of chromatin, makes it a promising target for small molecules. In addition, ANK3's involvement in the regulation of cancer cell migration and invasion, as well as its dysfunction in the immune system, makes it a promising candidate for cancer biomarker research. Further research is needed to fully understand the role of ANK3 in these processes and to develop effective drug targets and biomarkers.

Protein Name: Ankyrin 3

Functions: In skeletal muscle, required for costamere localization of DMD and betaDAG1 (By similarity). Membrane-cytoskeleton linker. May participate in the maintenance/targeting of ion channels and cell adhesion molecules at the nodes of Ranvier and axonal initial segments. Regulates KCNA1 channel activity in function of dietary Mg(2+) levels, and thereby contributes to the regulation of renal Mg(2+) reabsorption (PubMed:23903368)

The "ANK3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANK3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets